BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 11, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 6/8 cls
Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) Jefferies Thomas Wei Price target Buy 14% $21.57
Leerink Joseph Schwartz Upgrade Outperform (from market perform)
Wei raised his target to $30 from $24 after Xiaflex collagenase met the co-primary endpoints in the Phase III IMPRESS I and II trials to treat Peyronie's disease (see B15). Auxilium said it plans to submit an sBLA to FDA by year end, and Wei said he remains "highly positive" on the approval of the injectable form of collagenase. Pfizer Inc. (NYSE:PFE) has European marketing rights from Auxilium, which has worldwide rights from BioSpecifics Technologies Corp. (NASDAQ:BSTC). Xiaflex is already approved to treat Dupuytren's contracture in adult patients with a palpable cord.
Schwartz also raised his target to $25 from $20...

Read the full 894 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >